Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Hisamitsu IshiharaMasayo Yamada

Abstract

The global pandemic of type 2 diabetes mellitus (T2DM) is an enormous clinical and socioeconomic burden. Biguanides and DPP-4 inhibitors (DPP-4i) are the most commonly used therapies in Japanese T2DM patients. When glycemic control is not adequate despite combination of these drugs, there is no consensus on the next step drug. Systematic reviews and meta-analyses of previous trials have indicated that glycemic control with triple combination therapies yields similar results. Thus, beneficial effects on cardiovascular risk factors may be important. The present study was designed to evaluate body fat percentage and several insulin resistance parameters after addition of tofogliflozin or glimepiride to the regimens of patients being treated with metformin and a DPP-4 inhibitor but failing to attain adequate blood glucose control. Sodium glucose cotransporter-2 inhibitor, tofogliflozin versus glimepiride, comparative trial in patients with type 2 diabetes on body composition is an ongoing, multicenter, prospective, randomized, open-label, parallel-group trial. T2DM patients treated with metformin/DPP-4 inhibitor dual therapy have been recruited and randomly assigned to 20 mg/day tofogliflozin (n = 32) or 0.5 mg/day glimepiride (n =...Continue Reading

References

Jan 22, 2009·Metabolism: Clinical and Experimental·Takahiro ArakiYoshiki Nishizawa
Jan 25, 2011·Diabetes Research and Clinical Practice·Naoto KatakamiYoshimitsu Yamasaki
Aug 13, 2011·Journal of Human Hypertension·J BlacherM E Safar
Mar 14, 2012·The Journal of Pharmacology and Experimental Therapeutics·Masayuki SuzukiSachiya Ikeda
Jun 21, 2014·The Lancet. Diabetes & Endocrinology·Martin RidderstråleUNKNOWN EMPA-REG H2H-SU trial investigators
May 31, 2015·Diabetes Research and Clinical Practice·Suguru YamaguchiHisamitsu Ishihara
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 25, 2015·Current Medical Research and Opinion·G Lozano-OrtegaJ Mukherjee
Jun 21, 2016·Diabetes Research and Clinical Practice·Crystal Man Ying LeeStephen Colagiuri
Jun 23, 2016·Journal of Diabetes Investigation·Azuma KanatsukaAtsuyoshi Yuhara
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Jan 10, 2018·Diabetes, Obesity & Metabolism·Ren MatsubaYasushi Tanaka

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Software Mentioned

SAS

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.